Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms by Site: full-pipeline trial registry
7 of 12 indexed Neoplasms by Site trials are currently recruiting.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Neoplasms by Site: 12 US clinical trials tracked, 7 recruiting.
Neoplasms by Site is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Promontory Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition neoplasms-by-site
OPEN 7 | RECR 58% | LATE 4 | EARLY 6 | RANK #1429 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)
Neoplasms by Site lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms by Site on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms by Site is recruiting above its size-band peers.
7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neoplasms by Site trials is spread across many organizations.
Promontory Therapeutics accounts for 1 of 12 trials (8.3%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms by Site enrolment sits around 109 participants.
Median target enrolment is 109 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Neoplasms by Site research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
NCT06004440
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
NCT07222800
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics
NCT05386108
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT04572451
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics
NCT02266745
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Celgene
NCT01964430
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
NCT01629758
Studying Normal Breast Tissue and Cancer Risk
National Cancer Institute (NCI)
NCT00341692
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms by Site records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms by Site trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms by Site page
12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Neoplasms by Site trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Promontory Therapeutics sponsors the most Neoplasms by Site trials on record, review their full trial history before evaluating a specific study. See Promontory Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms by Site condition card totals 12 registered trials; most-linked intervention Denenicokin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.